全文获取类型
收费全文 | 1469985篇 |
免费 | 103798篇 |
国内免费 | 2334篇 |
专业分类
耳鼻咽喉 | 20745篇 |
儿科学 | 48293篇 |
妇产科学 | 41735篇 |
基础医学 | 214974篇 |
口腔科学 | 40055篇 |
临床医学 | 123752篇 |
内科学 | 293935篇 |
皮肤病学 | 31716篇 |
神经病学 | 116930篇 |
特种医学 | 55840篇 |
外国民族医学 | 457篇 |
外科学 | 221637篇 |
综合类 | 27324篇 |
现状与发展 | 1篇 |
一般理论 | 358篇 |
预防医学 | 110526篇 |
眼科学 | 33036篇 |
药学 | 111482篇 |
1篇 | |
中国医学 | 3086篇 |
肿瘤学 | 80234篇 |
出版年
2019年 | 11419篇 |
2018年 | 18315篇 |
2017年 | 13190篇 |
2016年 | 14314篇 |
2015年 | 16350篇 |
2014年 | 20909篇 |
2013年 | 32302篇 |
2012年 | 47543篇 |
2011年 | 49857篇 |
2010年 | 28085篇 |
2009年 | 25101篇 |
2008年 | 46891篇 |
2007年 | 50693篇 |
2006年 | 50159篇 |
2005年 | 49326篇 |
2004年 | 47086篇 |
2003年 | 45156篇 |
2002年 | 44124篇 |
2001年 | 62578篇 |
2000年 | 64141篇 |
1999年 | 54698篇 |
1998年 | 14934篇 |
1997年 | 13399篇 |
1996年 | 13605篇 |
1995年 | 12844篇 |
1994年 | 12198篇 |
1992年 | 43327篇 |
1991年 | 42463篇 |
1990年 | 41916篇 |
1989年 | 40529篇 |
1988年 | 37815篇 |
1987年 | 36899篇 |
1986年 | 35179篇 |
1985年 | 33481篇 |
1984年 | 24917篇 |
1983年 | 21673篇 |
1982年 | 12895篇 |
1981年 | 11342篇 |
1979年 | 23531篇 |
1978年 | 16489篇 |
1977年 | 14293篇 |
1976年 | 13462篇 |
1975年 | 14807篇 |
1974年 | 17412篇 |
1973年 | 16837篇 |
1972年 | 16004篇 |
1971年 | 14921篇 |
1970年 | 13876篇 |
1969年 | 13421篇 |
1968年 | 12566篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
81.
Rosario Gulias-Cañizo Anell Lagunes-Guillén Arturo González-Robles Erika Sánchez-Guzmán Federico Castro-Muñozledo 《Burns : journal of the International Society for Burn Injuries》2019,45(2):398-412
Background
Since recent reports have shown that (-)-Epigallocatechin-3-gallate (EGCG) could be used for treating proliferative and inflammatory disorders, we explored its use for the management of corneal chemical burns.Materials and methods
Initially, EGCG was assayed on the rabbit corneal epithelial cell line RCE1(5T5) to establish the best testing conditions, and to avoid unwanted outcomes in the experimental animals. Then, we studied its effects on cell proliferation, cell cycle progression and cell differentiation. Afterwards, we instilled EGCG in experimental grade II corneal alkali burns in mice, three times a day up to 21 days, and evaluated by slit lamp examination and histological sections of corneal epithelial, corneal endothelial and stromal edema, as well as the presence of inflammatory cells and neovascularization.Results
EGCG reduced cell growth and led to a decline in the proportion of proliferative cells in a concentration dependent manner. At 10 μM, EGCG promoted cell differentiation, an effect not related with apoptosis or cytotoxicity. When 10 μM EGCG was instilled in corneal alkali burns in mice three times a day up to 21 days, EGCG significantly reduced corneal opacity and neovascularization. The improved clinical appearance of the cornea was associated to a controlled epithelial growth; epithelial morphology was similar to that observed in normal epithelium and contrasted with the hyperproliferative, desquamating epithelium observed in control burn wounds. EGCG reduced corneal, stromal and endothelial edema, and wound inflammation.Conclusion
This work constitutes the first evidence for the use of EGCG in the acute phase of a corneal alkali burn, representing a possible novel alternative to improve patient outcomes as an add-on therapy. 相似文献82.
83.
84.
85.
86.
87.
88.
Michael E Egger Joanna M Ohlendorf Charles R Scoggins Kelly M McMasters Robert C G Martin II 《HPB : the official journal of the International Hepato Pancreato Biliary Association》2015,17(9):839-845
BackgroundThe aim of this paper is to assess the current state of quality and outcomes measures being reported for hepatic resections in the recent literature.MethodsMedline and PubMed databases were searched for English language articles published between 1 January 2002 and 30 April 2013. Two examiners reviewed each article and relevant citations for appropriateness of inclusion, which excluded papers of liver donor hepatic resections, repeat hepatectomies or meta-analyses. Data were extracted and summarized by two examiners for analysis.ResultsFifty-five studies were identified with suitable reporting to assess peri-operative mortality in hepatic resections. In only 35% (19/55) of the studies was the follow-up time explicitly stated, and in 47% (26/55) of studies peri-operative mortality was limited to in-hospital or 30 days. The time period in which complications were captured was not explicitly stated in 19 out of 28 studies. The remaining studies only captured complications within 30 days of the index operation (8/28). There was a paucity of quality literature addressing truly patient-centred outcomes.ConclusionQuality outcomes after a hepatic resection are inconsistently reported in the literature. Quality outcome studies for a hepatectomy should report mortality and morbidity at a minimum of 90 days after surgery. 相似文献
89.
90.